Low-intensity Extracorporeal Shockwave Therapy for the Management of Postprostatectomy Erectile Dysfunction: A Systematic Review of the Literature

Maria Chiara Sighinolfia, Ahmed Eissab, Carlo Bellorofonte, Alessandro Mofferdinc, Mosaab Eldeebb, Simone Assummaa, Enrico Panic, Tommaso Calcagnile, Daniele Stroppaa, Giorgio Bozzini, Giorgia Gaifa, Stefano Terzonia, Mattia Sangalli, Salvatore Micalid, Bernardo Roccoca

Urology Department, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy; Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt; Urology Unit, Columbus Clinic Center, Milan, Italy; Urology Department, University of Modena & Reggio Emilia, Modena, Italy; Urology Department, ASST Lariana, Como, Italy; Gynecology Department, ASST Santi Paolo e Carlo, Milan, Italy

Article info

Accepted July 7, 2022

Associate Editor: Silvia Proietti

Keywords:
- Low-intensity extracorporeal shockwave therapy
- Erectile dysfunction
- Radical prostatectomy

Abstract

Context: Erectile dysfunction (ED) following radical prostatectomy is a concern for patients and their partners. Low-intensity extracorporeal shockwave therapy (LI-ESWT) can potentially enhance tissue repair and regeneration. The aim of the current study was to systematically review the literature to assess the role of LI-ESWT in the management of patients with postprostatectomy ED.

Evidence acquisition: Two authors independently performed a systematic search of the PubMed and Web of Science databases to identify all relevant articles. Non-English reports, case reports, reviews, letters, and editorials were excluded. Risk of bias was assessed according to the GRADE guidelines.

Evidence synthesis: Nine articles met the inclusion criteria and were included in the qualitative analysis. All the studies included were published between 2015 and 2022 and the majority of them compared phosphodiesterase type 5 inhibitors (PDE5Is) alone versus a combination of LI-ESWT and PDE5Is. Only three studies were randomized controlled trials (RCTs). In general, there is no standardized protocol for LI-ESWT for postprostatectomy ED. In comparisons of LI-ESWT + PDE5Is versus PDE5Is alone, some authors found a statistically significant improvement in erectile function with LI-ESWT + PDE5Is. The starting time for LI-ESWT differed among the studies, ranging from 3 d to 6 mo after surgery. The main limitations of the review are the scarcity of studies, small sample sizes, high risk of bias, and high heterogeneity among studies.

* Corresponding author. Department of Urology, Tanta University Hospitals, Al-Giesh Street, El-Gharbia 31527, Tanta, Egypt. Tel. +2 11 10304666. E-mail address: ahmed.essa@med.tanta.edu.eg (A. Eissa).
1. Introduction

A survey-based study showed that erectile dysfunction (ED) is the most distressing problem after radical prostatectomy (RP) over the long term, the impact of which on patients’ quality of life is greatly underestimated by surgeons [1]. Considering the important role of the neurovascular bundle (NVB) located at the posterolateral aspect of the prostate, a nerve-sparing approach to RP was proposed in the early 1980s to enhance postoperative erectile function [2], but ED has persisted as a life-distressing sequela of RP for patients and their partners [1]. This is because nerve injury is not limited to partial or total sectioning but may also be attributable to the neuropraxia that results from compression, traction, coagulation, ischemia, and inflammation of the tissues in the NVB region [3,4]. In addition, arterial insufficiency resulting from injury to the lateral and apical accessory pudendal arteries during RP may play a role in the pathophysiology of postprostatectomy ED [5].

To enhance the recovery of erectile function after RP, different strategies for penile rehabilitation have been investigated, including intracavernosal injection of prostaglandin E1, phosphodiesterase type 5 inhibitors (PDE5Is), intraurethral and topical alprostadil, and vacuum erectile devices. However, after 25 yr, the optimal penile rehabilitation strategy is still a matter of debate [6].

Preclinical studies showed that low-intensity extracorporeal shockwave therapy (LI-ESWT) enhances tissue regeneration via its shear stress effect (microtrauma and mechanical stress effects on deep tissue), which subsequently increases the expression of VEGF and endothelial nitric oxide synthase, causing tissue neoangiogenesis and thus improving its blood flow [7]. Subsequently, there was an increase in interest in the use of LI-ESWT in the management of vasculogenic ED [3]. In 2016, Li et al. [8] reported for the first time that LI-ESWT could potentially improve erectile function in Sprague-Dawley rats with bilateral cavernous nerve injury via activation of Schwann cell proliferation and an increase in neuronal nitric oxide synthase. Subsequently, several authors assessed the impact of this energy on the treatment of patients with postprostatectomy ED [3,4,9–15]. The aim of the current study was to systematically review the literature to assess the value of LI-ESWT in the management of patients with postprostatectomy ED.

2. Evidence acquisition

2.1. Search strategy

A systematic search of the PubMed and Web of Science databases in April 2022 performed by two authors (A.E. and M.E.) using a combination of different keywords (Supplementary material) identified 471 reports, of which 174 were excluded as they were duplicates (Fig. 1). Screening of the remaining 297 articles by title and abstract resulted in exclusion of 271 (irrelevant, vasculogenic ED, reviews, letters, editorials, and case reports). Full-text assessment was performed for the remaining 26 articles. Finally, nine articles were included in the final review (Table 1). The review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary material) [16].

2.2. Quality assessment

Assessment of the risk of bias is reported and discussed in the Supplementary material.

3. Evidence synthesis

3.1. Characteristics of the studies included

All the studies included were published between 2015 and 2022. Only three studies were randomized controlled trials (RCTs), of which two compared the combination of PDE5Is and LI-ESWT versus PDE5Is alone [4,14] and one compared LI-ESWT versus a sham protocol in the management of postprostatectomy ED [9]. Furthermore, three reports were nonrandomized comparative studies [10,12,15] and two reports described noncomparative experience with LI-ESWT use in single centers for postprostatectomy ED [3,13]. One conference abstract was included owing to the scarcity of data on this topic in the literature [11].

In terms of the geographic distribution of the studies, two were carried out in Denmark [9,13] and one in each of Egypt [14], Brazil [4], Turkey [10], Germany [3], South Korea [15], Japan [12], and the USA [11]. The authors reported no conflicts of interest and an absence of funding, except for the study by Frey et al. [13], for which the
authors declared their potential conflicts of interest and that the ESWT machine was provided by Storz Medical.

3.2. LI-ESWT for postprostatectomy ED

In 2013, Inoue et al. [17] reported on LI-ESWT use for the management of five middle-aged men (mean 63.2 yr) with ED, of whom three had ED following laparoscopic RP and two suffered from vasculogenic ED. The authors reported that LI-ESWT has the potential to significantly improve the Erectile Hardness Score (EHS) for patients suffering from vasculogenic ED but not for patients with ED following laparoscopic RP. However, it should be noted that the three RP patients in this study underwent non–nerve-sparing RP [17]. These findings were confirmed by Chung et al. [18], who included 3/30 patients suffering from ED after RP and reported that LI-ESWT was associated with a statistically significant improvement in erectile function for patients with vasculogenic ED in comparison to those with postprostatectomy ED. In their pioneering work in 2015, Frey et al. [13] demonstrated that LI-ESWT can potentially improve erectile function in patients with ED following bilateral nerve-sparing RP, which raised urologists’ interest in investigating the value of LI-ESWT in patients with postprostatectomy ED [2–4,9–15].

There is no standardized LI-ESWT protocol for patients with postprostatectomy ED. For instance, some authors reported a protocol consisting of one session weekly...
RCTs [4,9,11], while others reported two sessions [10,12–14] or even up to three sessions per week [12,15]. Similarly, the total number of sessions (ranging from 5 sessions [9] to 12 [10,12,14]), the number of shockwave per session (ranging from 1500 [10,12,14,15] to 10 000 [11]), and the wave frequency (ranging from 120 [12,14,15] to 300 [4,9,13] waves/min) were highly variable. Most studies divided the number of shockwaves administered per sessions over five main regions of the penis, consisting of the right crura, the left crura, the root, the shaft, and the tip of the penis [4,10,12,14,15], except for Ladegaard et al. [9], who split the shockwaves over eight regions by dividing the penile root, shaft, and tip into right and left regions. Energy flux density (EFD), defined as energy per area, of 0.09 mj/mm² was the setting most commonly used [4,10–12,14,15], while higher EFD settings (0.15–0.30 ml/mm²) were reported in three studies [3,9,13]. These protocol heterogeneities can be explained by the use of different shockwave machines with different energy sources. Porst [3] reviewed shockwave machines used for the treatment of ED and found that each device provides a different EFD range that yields different total energy per shot and thus a different experience for the patient.

All the studies included in our review evaluated middle-aged men (mean age ranging from 52.9 yr [14] to 66.6 yr [12]) suffering from postprostatectomy ED mainly secondary to nerve-sparing RP. Only one RCT assessed the value of LI-ESWT in the management of ED secondary to nerve-sparing radical prostatectomy [14]. The authors randomized patients to receive LI-ESWT, PDE5is, or no treatment at all. Although they found no statistically significant differences among the three groups, LI-ESWT and PDE5is were associated with 16% and 19% better recovery of potency, respectively, when compared to the no-treatment group [14]. Several authors compared a penile rehabilitation protocol consisting of a combination of LI-ESWT and PDE5is versus PDE5is alone, reporting a significant improvement in erectile function with the combination protocol when compared to the PDE5is protocol [3,4,9–11,15]. This finding was further confirmed when considering only the results from RCTs [4,9]; however, it should be noted that not all the statistically significant findings are of clinical importance, as 17.1% vs experimental group 22.2%; \( p = 0.57 \). This finding is in line with the outcomes reported by Ericson et al. [11], who demonstrated similar results (36.4% for PDE5is + LI-ESWT vs 25% for PDE5is alone; \( p = 0.51 \)). Similarly, Jang et al. [15] reported that only 29.3% of patients experienced a clinically significant improvement in EHS (≥3) at 6 mo in a cohort undergoing penile rehabilitation with a LI-ESWT + PDE5is protocol, compared to 10.3% of patients using only PDE5is. However, these studies had small sample sizes and short follow-up.

The most recent meta-analysis of RCTs on penile rehabilitation protocols after radical prostatectomy reported that only regular sildenafil 100 mg intake (nightly or daily doses) and pelvic floor muscle training were associated with enhanced recovery of potency, yet none of the studies included in our review reported on the use of sildenafil 100 mg or pelvic floor muscle training in their penile rehabilitation protocol [6]. Most authors reported daily intake of tadalafil 5 mg [3,4,10,15], except one study that used sildenafil 50 mg daily [14].

The starting time for LI-ESWT differed among the studies, ranging from 3 d [10] to 6 mo [12] after surgery. Inoue et al. [12] suggested that early LI-ESWT application may improve neural recovery by enhancing cavernosal blood flow and preventing penile remodeling, while late LI-ESWT may play an important role in reversing penile fibrotic remodeling [12]. The authors compared early (starting 1–2 wk after surgery) versus delayed (starting 6 mo after surgery) LI-ESWT and found that early LI-ESWT sessions before catheter removal were associated with better recovery of sexual function when compared to the delayed protocol. However, this study has many limitations, including a small sample size and an inability to control confounding factors such as the percentage of patients undergoing nerve-sparing surgery (20% in the early protocol group vs 63.3% in the delayed protocol group) [12].

To date, there is no standardized tool for reporting sexual function outcomes following RP, which represents an obstacle towards defining the ideal management option for post-prostatectomy ED. It is noteworthy that not all statistically significant improvements in results for the tools currently available truly reflect patients’ satisfaction and perception of treatment success [19]. The studies included showed high heterogeneity regarding the tools used for assessment of postoperative erectile function. Some studies used only IIEF-5 [4,10,13], EHS alone [15], a combination of EHS and IIEF-5 [9,11], or other measures (such as sexual bother and sexual function scores assessed as a part of the Expanded Prostate Cancer Index Composite questionnaire and IIEF) [12,14]. Regardless of the tool used, return of sexual function to the preoperative baseline is considered the most realistic measure of sexual function following RP [19].

Incontinence is another distressing problem that may occur after RP. Only two studies evaluated the hypothesis that LI-ESWT may affect postoperative continence function, and reported no significant difference between patients receiving LI-ESWT and those who did not [4,10]. Similarly, Zewin et al. [14] reported no significant difference in continence function following radical cystoprostatectomy among LI-ESWT, PDE5is, and control groups.

The current review is not devoid of limitations. First, owing to the scarcity of studies, we decided to include a conference abstract that did not provide all the data required for full evaluation of the study. Second, most of the observational studies included in the review were characterized by high risk of bias and short follow-up. Third, the sample size in almost all of the studies included is small, with a cumulative total of 230 patients across all the studies published in the literature. Fourth, we did not perform a meta-analysis because of the scarcity of studies addressing this topic and the high heterogeneity among the studies included in the review. Furthermore, it was not possible to discuss the clinical outcomes of LI-ESWT in relation to the treatment proto-
| Study        | N  | Patients’ characteristics | Protocol | ESWT machine | Sessions (n) | Time/session | Regions | No. of waves | Frequency | EFD (mJ/mm²) | Outcomes | Notes                                                                                                                                 |
|-------------|----|---------------------------|----------|--------------|--------------|--------------|---------|--------------|-----------|--------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------|
| Jang 2022   | 39 | Age: 66 yr PSA: 6.32 ng/ml IIEF-5 score: 18 BMI: 24.36 kg/m² DM: 30.8% EHS: 3 | Tadalafil 5 mg starting from week 1 to 6 mo after RP | NA          | NA           | NA          | NA      | NA           | NA        | NA           | EHS ≥ 3    | 3 wk: 0% 1 mo: 5.1% 3 mo: 5.1% 6 mo: 10.3% No significant difference between the groups except at 6 mo (p = 0.034) On multivariate logistic regression LI-ESWT was the only significant predictor of EHS ≥ 3 at 6 mo |
|             |    |                           |          |              |              |              |         |              |           |              |           |                                                                                                                                 |
| Porst 2021  | 41 | Age: 62 yr PSA: 7 ng/ml IIEF-5 score: 19 BMI: 24.88 kg/m² DM: 14.6% EHS: 3 | Tadalafil 5 mg starting week 1 to 6 mo after RP + LI-ESWT on days 4, 5, 6, and 7 and in weeks 2 and 4 after RP | Omnispec ED1000 (EH) | 6          | 15 min      | Right crus | Left crus | 1/3 root | 1/3 middle | 1/3 tip | 1500 (300 per region) 120/min 0.09 | EHS ≥ 3    | 3 wk: 14.6% 1 mo: 12.2% 3 mo: 14.6% 6 mo: 29.3%                                                                                                                                 |
|             |    |                           |          |              |              |              |         |              |           |              |           |                                                                                                                                 |
| Karakose 2021 | 12 | NA                        | Tadalafil 5 mg, starting 5 d pre RP + LI-ESWT 8–14 d after RP | Dornier Aries 2 (EM) MTS Urogold 100 (EH) PiezoWave (PE) | 6–10        | NA          | NA        | NA          | Up to 0.30 | Success rate 83.3%                                                                                                              |           | 10 patients returned to pre RP IIEF; 2 patients reported failed treatment, but had impaired EF before RP |
|             |    |                           |          |              |              |              |         |              |           |              |           |                                                                                                                                 |
|             | 32 | Age: 58.4 ± 6.7 yr PV: 34.5 ± 15.3 ml PSA: 9.9 ± 7.8 ng/ml IIEF-5 score: 21 ± 3.6 BMI: 28.7 ± 4.8 kg/m² DM: 12.5% HTN: 21.8% CAD: 18.7% | Only tadalafil 5 mg starting on day 3 after RP | Omnispec ED1000 (EH) | 12         | 20 min       | Right crus | Left crus | 1/3 root | 1/3 middle | 1/3 tip | 1500 (300 per region) 160/min 0.09 | IIEF-5 score 3: 7 ± 2.8 6: 7 ± 2.9 12: 9 ± 3.4 | IIEF-5 was assessed at 3, 6, and 12 mo after RP |
|             |    |                           |          |              |              |              |         |              |           |              |           |                                                                                                                                 |
|             | 34 | Age: 59.2 ± 6.8 yr PV: 35.1 ± 17.2 ml PSA: 9.9 ± 5.3 ng/ml IIEF-5 score: 21 ± 2.8 BMI: 28.4 ± 5.1 kg/m² DM: 14.7% HTN: 23.5% CAD: 17.6% | Tadalafil 5 mg starting on day 3 after RP + LI-ESWT (2 sessions/wk starting 3 mo after RP) | Omnispec ED1000 (EH) | 12         | 15 min       | Right crus | Left crus | 1/3 root | 1/3 middle | 1/3 tip | 1500 (300 per region) 160/min 0.09 | IIEF-5 score 3: 7 ± 2.2 6: 13 ± 3.3 12: 18 ± 3                                                                 |           |                                                                                                                                 |
| Inoue 2020  | 5  | Age: 62.2 ± 2.68 PV: 25.2 ± 5.76 ml PSA: 4.95 ± 2.82 ng/ml SF score: 66.5 SB score: 86.3 BMI: 24.5 ± 1.25 kg/m² | Early LI-ESWT of 3 sessions/wk for the first 2 wk after RP then once weekly for 6 wk | Omnispec ED1000 (EH) | 12         | 20 min       | Right crus | Left crus | 1/3 root | 1/3 middle | 1/3 tip | 1500 (300 per region) 120/min 0.09 | SF score 6: 19.2 9: 20.9 12: 28 SB score 3: 33.8 6: 46.3 9: 61.3 | SF and SB were assessed using the EPIC score at 0, 3, 6, 9, and 12 mo after RP |

(continued on next page)
| Study         | N   | Patients’ characteristics | Protocol                                                                 | ESWT machine | Sessions (n) | Time/session | Regions | No. of waves | Frequency | EFD (mJ/mm²) | Outcomes | Notes             |
|--------------|-----|---------------------------|---------------------------------------------------------------------------|--------------|--------------|--------------|---------|--------------|-----------|-------------|-----------|------------------|
|              |     |                           | T: 4.24 ± 0.78 ng/ml                                                      | NSS: 20%     |              |              |         |              |           |             | 12 mo: 56.3 |                  |
|              | 11  | Age: 62.9 ± 1.80 yr PV: 25.2 ± 5.76 ml PSA: 6.39 ± 1.90 ng/ml SF score: 41.8 SB score: 69.9 BMI: 23.3 ± 0.84 kg/m² T: 4.82 ± 0.58 ng/ml NSS: 63.6% | Delayed LI-ESWT starting 6 mo after RP: 2 sessions/ wk for 3 wk, followed by 3 wk of rest, then 2 sessions/wk for 3 wk | Omnispec ED1000 (EH) | 12 | 20 min | Right crus 1/3 root 1/3 middle 1/3 tip | 1500 (300 per region) | 120/min | 0.09 | SF score 6 mo: 17.9 9 mo: 25.8 12 mo: 21.3 | At 16 wk SF score 6 mo: 17.9 9 mo: 25.8 12 mo: 21.3 SB score 3 mo: 41.9 6 mo: 54.2 9 mo: 71.9 12 mo: 82.3 The difference in IIEF-5 score was significant at the last follow-up visit, but did not reach the primary clinical endpoint of a difference of ≥4 points |
|              | 178 | Age: 66.6 ± 0.45 yr PV: 29.2 ± 0.97 ml PSA: 9.12 ± 0.47 ng/ml SF score: 31.8 SB score: 87.9 BMI: 23.4 ± 0.21 kg/m² T: 4.66 ± 0.13 ng/ml NSS: 43.8% | No LI-ESWT | – | – | – | – | – | – | – | SF score 6 mo: 8.1 9 mo: 10.2 12 mo: 9.5 | At 16 wk IIEF-5 ≥17: 17.1% |
| Baccaglini   | 41  | Age: 64.6 ± 5.3 yr BMI: 25.9 ± 2.7 kg/m² HTN: 53.7% DM: 19.5% Smoking: 4.9% IIEF-5 score: 22 | 5 mg/d radalafil after removal of urethral catheter (7–10 d) | – | – | – | – | – | – | – | – | At 16 wk IIEF-5: 10 IIEF-5 ≥17: 17.1% |
| [4]         |     |                           |                                           | Renova (DIREX group) (EM) | 8 | 8 min | Right crus 1/3 root 1/3 middle 1/3 tip | 2400 (600 per region) | 300/min | 0.09 | At 16 wk IIEF-5: 12 IIEF-5 ≥17: 22.2% |
| Ladegaard    | 20  | Age: 60.8 yr BNS: 35% UNS: 65% CAD: 55% DM: 10% Smokers: 15% PDE5I: 90% EHS score: 1.30 IIEF-5 score: 6.8 | One LI-ESWT session/wk for 5 wk | Duolith SD1 (EM) | 5 | NA | Right crus 1/3 root 1/3 middle 1/3 tip | 4000 | 300/min | 0.15 | At 4 wk EHS: +0.35 IIEF-5: +2.4 At 12 wk EHS: +0.5 IIEF-5: +3.45 | NA |
| 2020         | 18  | Age: 64.3 yr BNS: 28% UNS: 72% | Sham protocol | – | – | – | – | – | – | – | At 4 wk EHS: -0.17 IIEF-5: +1.28 | |
| Study | N | Patients’ characteristics | Protocol | ESWT machine | Sessions (n) | Time/session | Regions | No. of waves | Frequency | EFD (mJ/mm²) | Outcomes | Notes |
|-------|---|---------------------------|----------|--------------|--------------|--------------|---------|-------------|-----------|-------------|----------|-------|
| Zewin 2018 [14]a | 42 | Age: 52.9 ± 7.2 yr BMI: 27.2 ± 1 kg/m² Smokers: 21.4% IIEF score: 68.5 | Two LI-ESWT sessions/wk for 3 wk, repeated after 3 wk of no treatment | Zewin Aries (EM) | 12 | 15 min | Right crus | 1/3 root | 1/3 middle | 1/3 tip | 1500 | 120/min | At 12 wk EHS: -0.17 IIEF-5: +0.65 |
| | | | | | | | Left crus | 1/3 root | 1/3 middle | 1/3 tip | | | 16% more patients in the LI-ESWT group and 19% in the PDE5I group reported potency recovery compared to the sham group; this finding was not statistically significant but it was of clinical importance |
| | | | | | | | | 10% | | | | | |
| 43 | Age: 53.4 ± 5.9 yr BMI: 25.3 ± 0.9 kg/m² Smokers: 14% IIEF score: 68.8 | PDE5I (sildenafil 50 mg/d for 6 mo) | – | – | – | – | – | – | – | – | – | – | IIEF score 1 mo: 19.3 3 mo: 55.9 6 mo: 60.7 9 mo: 61.5 |
| 43 | Age: 51.2 ± 6.3 yr BMI: 26.8 ± 1.2 kg/m² Smokers: 16.3% IIEF score: 68.6 | No treatment | – | – | – | – | – | – | – | – | – | – | |
| Frey 2015 [13] | 6 | Age: 62 yr IIEF-5 score 25 before surgery 9.5 before ESWT | Two sessions per week every other week for 6 wk | DuoLith SD1 T-Top (EM) | 6 | NA | Root Shaft | 3000 | 300/min | 0.20 | 0.15 | 0.12 | At 12 mo, 3 patients discontinued their erectogenic aids |
| | | | | | | | Glans | | | | | | |
| Ericson 2020 [11]b | 29 | Age: 62.5 yr Pre-ESWT score (6 wk post-RP) SHIM: 5 EHS: 1 | PDE5I only | – | – | – | – | – | – | – | – | – | 12 wk SHIM: 6 EHS: 1 24 wk SHIM: 5 EHS: 1 Normal EF reported by 25% of patients at 3 mo |
| 23 | Age: 59.2 yr Pre-ESWT score (6 wk post-RP) SHIM: 7 EHS: 2 | Once weekly sessions over a period of 6 wk started 2 wk after RP + PDE5I | Zimmer enPuls 2.0 (EM) | 6 | NA | Corpora and cavernosal bundle bilaterally | 10,000 | NA | 0.09 | 12 wk SHIM: 7 EHS: 2 24 wk SHIM: 10 EHS: 2 Normal EF reported by 36.4% of patients at 3 mo |

BMI = body mass index; BNS = bilateral nerve-sparing; CAD = coronary artery disease; DM = diabetes mellitus; EF = erectile function; EFD = energy flux density; EH = electroydraulic; EHS = Erection Hardness Score; EM = electromagnetic; EPIC = Expanded Prostate Cancer Index Composite; HTN = hypertension; IIEF = International Index of Erectile Function; LI-ESWT = low-intensity extracorporeal shockwave therapy; NA = not applicable; NSS = nerve-sparing surgery; PDE5I = phosphodiesterase type 5 inhibitor; PE = piezoelectric; PSA = prostate-specific antigen; PV = prostate volume; RP = radical prostatectomy; SB = sexual bother score from EPIC; SF = sexual function score from EPIC; SHIM = Sexual Health Inventory for Men; T = testosterone; UNS = unilateral nerve-sparing.  

a Randomized controlled trial.  
b Conference abstract.
col owing to the high heterogeneity in terms of the tools used for assessment of erectile function and patient follow-up. Finally, not all of the studies included used LI-ESWT in a penile rehabilitation setting, as some studies used LI-ESWT for the treatment of postprostatectomy ED. However, to the best of our knowledge, this is the first systematic review in the literature addressing this topic.

4. Conclusions

There is currently limited evidence in the literature on the use of LI-ESWT either alone or in combination with PDE5is in penile rehabilitation protocols after RP. However, initial results obtained from preclinical studies on animal models and small clinical trials with short follow-up show that LI-ESWT may potentially play a role in the management of postprostatectomy ED in the future. Further RCTs with large sample sizes are required to support these findings.

Author contributions: Maria Chiara Sighinolfi had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Sighinolfi, Eissa, Bellorofonte, Mofferdin, Eldeeb.

Acquisition of data: Sighinolfi, Eissa, Bellorofonte, Mofferdin, Eldeeb, Assumma, Panio, Calcagnile.

Analysis and interpretation of data: Sighinolfi, Eissa, Eldeeb, Assumma, Panio, Calcagnile, Stroppa.

Drafting of the manuscript: Sighinolfi, Eissa.

Critical revision of the manuscript for important intellectual content: Bozzini, Gaia, Terzoni, Sangalli, Micalli, Rocco.

Statistical analysis: Eissa, Eldeeb.

Obtaining funding: None.

Supervision: Bozzini, Gaia, Micalli, Rocco.

Other: None.

Financial disclosures: Maria Chiara Sighinolfi certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.euros.2022.07.003.

References

[1] Chartier-Kastler E, Amar E, Chevallier D, et al. Does management of erectile dysfunction after radical prostatectomy meet patients' expectations? Results of a national survey (REPAIR) by the French Urological association. J Sex Med 2008;5:693–704. https://doi.org/10.1111/j.1743-6109.2007.00743.x.

[2] Walsh PC, Lepor H, Eggelston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983;4:473–85. https://doi.org/10.1002/pro.2990040506.

[3] Porst H. Review of the current status of low intensity extracorporeal shockwave therapy (LI-ESWT) in erectile dysfunction (ED), Peyronie's disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients. Sex Med Rev 2021;9:93–122. https://doi.org/10.1016/j.sxmr.2020.01.006.

[4] Baccaglini W, Pazeto CL, Corrêa Barros EA, et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med 2020;17:688–94. https://doi.org/10.1016/j.jsxm.2019.12.024.

[5] Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009;55:334–47. https://doi.org/10.1016/j.eururo.2008.10.028.

[6] Sari Motlagh R, Abufaraj M, Yang L, et al. Penile rehabilitation strategy after nerve sparing radical prostatectomy: a systematic review and network meta-analysis of randomized trials. J Urol 2021;205:1018–30. https://doi.org/10.1097/JU.0000000000001584.

[7] Zou Z-J, Liang J-Y, Liu Z-H, Gao R, Lu Y-P. Low-intensity extracorporeal shock wave therapy for erectile dysfunction after radical prostatectomy: a review of preclinical studies. Int J Impot Res 2018;30:1–7. https://doi.org/10.1038/s41443-017-0002-6.

[8] Li H, Matheu MP, Sun F, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. J Sex Med 2016;13:22–32. https://doi.org/10.1016/j.jsxm.2015.11.008.

[9] Ladegaard PBJ, Mortensen J, Skov-Jeppesen SM, Lund L. Erectile dysfunction a prospective randomized placebo-controlled study evaluating the effect of low-intensity extracorporeal shockwave therapy (LI-ESWT) in men with erectile dysfunction following radical prostatectomy. Sex Med 2021;9:100338. https://doi.org/10.1016/j.jsxm.2021.100338.

[10] Karakose A, Yitgin Y. Penile rehabilitation with low-intensity extracorporeal shock wave therapy in patients after prostate cancer surgery. Early physiological changes and postoperative follow-up outcomes. Int J Clin Pract 2021;75:e14804. https://doi.org/10.1111/ijcp.14804.

[11] Ericson K, Murthy P, Bryk D, Shoskes D. A trial of low-intensity shockwave therapy for penile rehabilitation after radical prostatectomy. J Sex Med 2020;17:519–20. https://doi.org/10.1016/j.jsxm.2019.11.038.

[12] Inoue S, Hayashi T, Teishima J, Matsubara A. Effect of penile rehabilitation with low intensity extracorporeal shock wave therapy on erectile function recovery following robot-assisted laparoscopic prostatectomy. Transl Androl Urol 2020;9:1559–65. https://doi.org/10.21037/tau.19-888.

[13] Frey A, Senksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol 2016;50:123–7. https://doi.org/10.3109/21681805.2015.1100675.

[14] Zewin TS, El-Assmy A, Harraz AM, et al. Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial. Int Urol Nephrol 2018;50:2007–14. https://doi.org/10.1007/s11255-018-1987-6.

[15] Jang SW, Lee EH, Chun SY, et al. Comparison of the efficacy of the early LI-SWT plus daily tadalafl with daily tadalafl only as penile rehabilitation for postprostatectomy erectile dysfunction. Int J Impot Res 2022. https://doi.org/10.1038/s41443-022-00560-w.

[16] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339. https://doi.org/10.1136/bmj.b2700.

[17] Inoue S, Kurimura Y, Sadahide K, et al. PP-034 Low intensity extracorporeal shockwave therapy for erectile dysfunction in ED patients: initial experience in Japan. J Sex Med 2013;10:224. https://doi.org/10.1111/j.12182_3.
[18] Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial. BJU Int 2015;115:46–9. https://doi.org/10.1111/bju.13035.

[19] Lovegrove CE, Ficarra V, Montorsi F, N'Dow J, Salonia A, Minhas S. Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?. Int J Impot Res 2020;32:495–502. https://doi.org/10.1038/s41443-019-0220-1.